Qingya Cui Peiqi Liang Haiping Dai Wei Cui Mengjie Cai Zixuan Ding Qinfen Ma Jia Yin Zheng Li Sining Liu Liqing Kang Li Yao Jiannong Cen Hongjie Shen Mingqing Zhu Lei Yu Depei Wu Xiaowen Tang
10.3389/fimmu.2022.1012981
Front Immunol
2022 Nov 29;13:1012981.
cd38 blast phase chimeric antigen receptor t cell chronic myeloid leukemia tyrosine kinase inhibitor
CC BY
https://pubmed.ncbi.nlm.nih.gov/36524116/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Receptors, Chimeric Antigen / genetics Receptors, Chimeric Antigen / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Receptors, Chimeric Antigen / genetics Receptors, Chimeric Antigen / therapeutic use Case Reports Research Support, Non-U.S. Gov't Cell- and Tissue-Based Therapy Drug Resistance, Neoplasm / genetics Humans Immunotherapy Protein Kinase Inhibitors / pharmacology Protein Kinase Inhibitors / therapeutic use Receptors, Chimeric Antigen Protein Kinase Inhibitors
PMC9744919
36524116
Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
2022